Darunavir

證據等級: L5

預測適應症: 4 個

Darunavir: From HIV-1 Infection to Simian Immunodeficiency Virus Infection

One-Sentence Summary

Darunavir is a second-generation HIV-1 protease inhibitor. The TxGNN model predicts it may be effective for Simian Immunodeficiency Virus (SIV) Infection, an animal-model indication supported by 0 clinical trials and 4 publications (all non-human primate studies). This is a research-tool application, not a human therapeutic indication, and no marketing authorization exists in Germany.

Quick Overview

Item	Content
Original Indication	Not available (no licensed indication text in dataset; darunavir is a known HIV-1 protease inhibitor for HIV-1 infection)
Predicted New Indication	Simian Immunodeficiency Virus Infection
TxGNN Prediction Score	99.97%
Evidence Level	L3
Germany Market Status	未上市 (Not Marketed)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in this evidence pack (flagged as a Blocking/High-severity data gap). Based on known pharmacology, darunavir is a second-generation HIV-1 protease inhibitor that blocks viral polyprotein cleavage, preventing maturation of infectious virions.

SIV and HIV-1 are both lentiviruses with highly homologous protease structures. This structural similarity provides a plausible mechanistic rationale for darunavir's use in SIV-infected non-human primate (NHP) models — not as a novel human therapeutic, but as a component of combination antiretroviral therapy (cART) regimens used in HIV/AIDS cure research (viral reservoir studies, eradication strategies). This is consistent with darunavir's known pharmacology and explains why the model assigns it a high prediction score for this "indication."

It should be noted that three other TxGNN-predicted indications in this evidence pack were assessed as not reasonable and are held at S0/L4-L5 with a "Hold" recommendation:

Feline AIDS (FIV): likely a knowledge-graph entity confusion (FIV ≠ HIV); the only linked trial is actually a human HIV study, unrelated to cats.
Neurodevelopmental disorder (white matter/ataxic gait): no mechanistic link, no evidence — pure model artifact.
Familial combined hyperlipidemia: mechanistically backwards — protease inhibitors are known to cause dyslipidemia, not treat it; the disease label itself is also obsolete.

Clinical Trial Evidence

Currently no related clinical trials registered for Simian Immunodeficiency Virus Infection.

(Note: one Phase 4 trial, NCT02770508, was linked to the "feline AIDS" prediction but was assessed as irrelevant — it studies human HIV-1 patients, not cats, and is excluded from this indication's evidence base.)

Literature Evidence

PMID	Year	Type	Journal	Key Findings
26150024	2016	Animal Study (NHP)	AIDS Research and Human Retroviruses	Evaluated coformulated injectable cART regimens (including darunavir components) in SIV-infected rhesus macaques
25033210	2014	Animal Study (NHP)	PLoS One	Combination cART plus SAHA (HDAC inhibitor) in SIV-infected Chinese rhesus macaques; viral reservoir research
22737073	2012	Animal Study (NHP)	PLoS Pathogens	Highly intensified ART regimen achieved long-term viral suppression and reservoir restriction in simian AIDS model
21505294	2011	Animal Study (NHP)	AIDS (London)	Auranofin combined with ART restricted viral reservoir in monkey AIDS model

Germany Market Information

Not marketed in Germany — no authorization records available (0 licenses on file).

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: All evidence for the SIV indication comes from non-human primate research-model studies (L3, no RCTs, no human clinical trials), and this is fundamentally a laboratory/animal-model tool use rather than a human therapeutic repurposing candidate. Combined with the absence of German market authorization and unresolved Blocking-severity safety data gaps (TFDA label/warnings, MOA), the candidate does not meet the threshold to advance.

To proceed, the following is needed:

Resolve DG001 (Blocking): obtain official label warnings/contraindications before any S1 safety evaluation
Resolve DG002 (High): confirm mechanism of action via DrugBank API
Clarify intended use case — this is an NHP research-model application, not a human indication; confirm whether "repurposing" scope should even include animal-model/research-tool uses
If human application is intended, source primary human clinical evidence (none currently exists for SIV, which by definition does not infect humans)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.